[Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib und dexamethasone) - Benefit assessment according to ยง35a Social Code Book V - Addendum]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018003986
Original Title: Isatuximab (multiples Myelom, nach >= 1 Vortherapie - )Addendum zum Auftrag A21-60
Project Status: Completed
Year Published: 2021
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Antibodies, Monoclonal, Humanized
  • Multiple Myeloma
  • Antineoplastic Combined Chemotherapy Protocols
  • Isatuximab
  • Carfilzomib
  • Dexamethason
  • Multiple Myeloma
  • Benefit Assessment
  • NCT03275285
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.